Top Markets
#1 TENDIES TENDIES +59.72%
#2 Threshold Network Threshold Network +48.06%
#3 Cash Cat Cash Cat +25.61%
#4 Akedo Akedo +23.45%
#5 OSK OSK +16.28%
#6 Kinetiq Kinetiq +15.49%
#7 Maple Finance Maple Finance +14.59%
#8 Ape and Pepe Ape and Pepe +12.62%
#9 Falcon Finance Falcon Finance +12.36%
#10 Magma Finance Magma Finance +12.35%
Coin of the day
TENDIES TENDIES
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Neumora Therapeutics, Inc. Common Stock Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock

NMRA
Peringkat dalam Saham #17292
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company... Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Harga Saham
$1.35
Terakhir disinkronkan: 2026-09-01
Kapitalisasi Pasar
$249.21M
Perubahan (1 hari)
1.13%
Perubahan (1 tahun)
-22.70%
Negara
US
Perdagangan Neumora Therapeutics, Inc. Common Stock (NMRA)

Kategori

Healthcare
Rasio P/E untuk Neumora Therapeutics, Inc. Common Stock (NMRA)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Neumora Therapeutics, Inc. Common Stock, rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk Neumora Therapeutics, Inc. Common Stock dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.